Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Retooling The Sales Force Remains A Work In Progress

Executive Summary

Pharmaceutical sales reps may not relish the thought, but they could play leading roles in a Hollywood epic called 'The Incredible Shrinking Sales Force.' Between 2005 and the third quarter of 2009, the number of reps industry wide in the U.S. fell from 101,818 to 81,780, a 19.7 percent decline, according to SDI Health

You may also be interested in...



Out With Experimentation, ZS Sees New Commercial Models Settling In

After several years of experimentation, big pharma has settled on new commercial models for their U.S. sales teams and are in various stages of implementation, according to ZS Associates Managing Director Chris Wright. The preferred models have commonalities built around a mix of traditional sales reps, key account managers and multi-channel digital tools.

Pharma Promo Spending Mostly Level Despite Challenges

The pharmaceutical industry continues to invest heavily in promotional activities even as many drugs go off patent and new drug launches become less frequent.

Pharma's 2010 Promotional Budget: Fewer Reps But Same Dollars

Pharma's spending on product promotional activities in the United States has remained level over the past five years, even as companies continue with ambitious cost-cutting programs that have cut sales forces by more than 25%, according to the market research firm SDI.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel